Wednesday, April 8, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Google Updates COVID-19 Forecasting Models

In August, in partnership with the Harvard Global Health Institute, Google launched a set of models — the COVID-19 Public Forecasts — that provide projections of COVID-19 cases, deaths, ICU utilization, ventilator availability, and other metrics for U.S. counties and states. Today, the two organizations released what they claim are significantly improved models — trained on public data from Johns Hopkins University, Descartes Labs, the United States Census Bureau, and elsewhere — that expand beyond the U.S.

The COVID-19 Public Forecasts are intended to serve as a resource for first responders in health care, the public sector, and other affected organizations, Google says. The forecasts allow for targeted testing and public health interventions on a county-by-county basis, in theory enhancing users’ ability to respond to the rapidly evolving pandemic. For example, health care providers could incorporate the forecasted number of cases as a datapoint in resource planning for PPE, staffing, and scheduling. Meanwhile, state and county health departments could use the forecast of infections to inform testing strategies and identify areas at risk of an outbreak.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!